F10 and atrial fibrillation: Real-world use and effectiveness of FXa-inhibiting DOACs has been described previously in patients with AF in routine clinical practice [22–25], however, there is limited information regarding the impact of patient-related factors, including education and adherence, that may also influence treatment effectiveness.